| Name | Title | Contact Details |
|---|
Cortexyme is developing therapeutics based on data supporting a new theory of the cause of Alzheimer`s and other neurodegenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.
Roivant Sciences is a biopharmaceutical company focused on realizing the full value of promising drug candidates to improve the lives of patients and their families. Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. We are a unique biopharmaceutical company with world-class drug development experts working across multiple clinical and functional areas. Roivant delivers R&D solutions to our partners in the biopharmaceutical industry, helping them unlock value from their pipelines by completing the clinical development of promising drug candidates. Our company allows pharmaceutical companies to realize the full potential of their research while improving the lives of patients and their families. By reinventing drug development and investing in innovative R&D, Roivant will share the benefits of a more efficient drug development model with the healthcare system. Our pipeline spans multiple therapeutic areas through strategic alliances, collaborations and partnerships with academic institutions and pharmaceutical companies, including Takeda, Eisai, Vertex, Arena Pharmaceuticals, GlaxoSmithKline, Arbutus Biopharma, Duke University and Cincinnati Children’s Hospital Medical Center.
ZYTO Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
RiboCor is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Roche NimbleGen, Inc. is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.